Home › Companies › CGTX

Cognition Therapeutics

CGTX Lead: Phase 2 10 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-01-15

Pipeline (2 active programs)

zervimesine

CT1812

Small Molecule Target: σ-2 receptor, S2R complex

Alzheimer's Disease Phase 2 oral Alzheimer's Clinical Trial Consortium
Dementia with Lewy Bodies Phase 2 oral

Discontinued (1)

zervimesine — Geographic Atrophy · voluntarily discontinued to focus resources on dementia programs in AD and DLB; not related to safety concerns

Biotech Distilled coverage (10)

2026-06-24 UPDATE: Cognition Therapeutics (CGTX) — The Minutes Landed. The Stock Didn’t Get the Memo.
2026-05-21 UPDATE: Cognition Therapeutics (CGTX) - The May 20 Meeting Cleared, Now We Wait for the Minutes 🔒 Paid
2026-05-08 UPDATE: Cognition Therapeutics (CGTX) - The Psychosis Catalyst Has a Date 🔒 Paid
2026-03-29 UPDATE: Cognition Therapeutics (CGTX) - The Reality Check and a 30% Haircut 🔒 Paid
2026-03-22 UPDATE: Cognition Therapeutics (CGTX) – Showing the Math at AD/PD 🔒 Paid
2026-03-07 UPDATE: Cognition Therapeutics (CGTX) – The Psychosis Pivot is a Regulatory Masterstroke 🔒 Paid
2026-02-07 UPDATE: Cognition Therapeutics (CGTX) – Patients Vote Yes (But the Market Still Seems to Be Waiting) 🔒 Paid
2026-01-30 UPDATE: Cognition Therapeutics (CGTX) - The Phase 3 Dream Just Became a Phase 2b Reality Check 🔒 Paid
2026-01-07 UPDATE: Cognition Therapeutics (CGTX) Prints Some Receipts for DLB 🔒 Paid
2026-01-01 Cognition Therapeutics (CGTX): Scientific Due Diligence for Zervimesine 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.